Postoperatif radyoterapi ile eş zamanlı kapesitabin uygulanan lokal ileri evre rektum kanserli olgularda etkinlik ve tolerabilite değerlendirilmesi
Loading...
Date
2009-03-24
Authors
Aygün, Sevilcan
Journal Title
Journal ISSN
Volume Title
Publisher
Uludağ Üniversitesi
Abstract
Çalışmanın Amacı lokal ileri evre rektum kanserli olgularda postoperatif radyoterapi (RT) ile eş zamanlı kapesitabin uygulanmasının etkinliğini ve tolere edilebilirliğini değerlendirmektir. Mart 2004-Ocak 2007 tarihleri arasında Uludağ Üniversitesi Tıp Fakültesi Radyoterapi Merkezi’nde postoperatif radyoterapi ile eş zamanlı kapesitabin uygulanan evre II-III rektum adenokarsinomlu 26 olgu retrospektif değerlendirildi. Olgulara RT boost dozu ile birlikte toplam 50.4- 54 Gray (Gy), kapesitabin ortanca 1650 mg/m²/gün (minimum-maksimum : 13001650) dozda uygulandı. Ortanca iki yıllık genel sağkalım (GSK) oranı %80 olup, ortanca 19 aylık (minimum-maksimum: 1-30) izlem süresinde hiçbir olguda lokal yineleme görülmedi. Grade 3 lökopeni ve diyare sırasıyla bir (%4) ve iki (%8) olguda gözlendi. İzlem süresi ve olgu sayısının yetersizliğine rağmen lokal ileri evre rektum kanserinde radyoterapi ile eş zamanlı kapesitabin uygulanımı etkin ve tolere edilebilir olması nedeniyle alternatif tedavi olarak önerilebilir.
The purpose of this study was to evaluate the efficacy and the toxicity of concomitant chemoradiotherapy (CRT) with capecitabine in cases with locally advanced rectal cancer. 26 cases with stage II-III rectal adenocarcinoma, treated with postoperative CRT with capecitabine at Uludag University Faculty of Medicine Radiotherapy Center, between March 2004-January 2007, were evaluated retrospectively. The radiotherapy was delivered with a boost dose of 50.4-54 Gray (Gy) totally and capecitabine was given median 1650 mg/m²/day (range, 13001650). The median 2- year overall survival (OS) was 80%, and during the median follow-up time of 19 months (range, 1-30) there was no locoregional recurrence. Grade 3 leucopenia and diarrhea were observed in one (4%) and two (8%) cases, respectively. Although the insufficiency of follow-up time and the number of cases, we concluded that the concomitant postoperative chemoradiotherapy with capecitabine may be an effective and tolerabl treatment in locally advanced rectal cancer.
The purpose of this study was to evaluate the efficacy and the toxicity of concomitant chemoradiotherapy (CRT) with capecitabine in cases with locally advanced rectal cancer. 26 cases with stage II-III rectal adenocarcinoma, treated with postoperative CRT with capecitabine at Uludag University Faculty of Medicine Radiotherapy Center, between March 2004-January 2007, were evaluated retrospectively. The radiotherapy was delivered with a boost dose of 50.4-54 Gray (Gy) totally and capecitabine was given median 1650 mg/m²/day (range, 13001650). The median 2- year overall survival (OS) was 80%, and during the median follow-up time of 19 months (range, 1-30) there was no locoregional recurrence. Grade 3 leucopenia and diarrhea were observed in one (4%) and two (8%) cases, respectively. Although the insufficiency of follow-up time and the number of cases, we concluded that the concomitant postoperative chemoradiotherapy with capecitabine may be an effective and tolerabl treatment in locally advanced rectal cancer.
Description
Keywords
Rektum kanseri, Kapesitabin, Rectal cancer, Radyoterapi, Radiotherapy, Capecitabine
Citation
Aygün, S. vd. (2009). ''Postoperatif radyoterapi ile eş zamanlı kapesitabin uygulanan lokal ileri evre rektum kanserli olgularda etkinlik ve tolerabilite değerlendirilmesi''. Uludağ Üniversitesi Tıp Fakültesi Dergisi, 35(1), 21-25.